搜索结果：Cancer research and treatment

In oncology, recurrence after treatment is one of the major challenges, related to patients' survival and quality of life. Conventionally, prediction of cancer relapse has always relied on clinical observation with statistical model support, which almost fails to explain the complex, multifactorial nature of tumor recurrence. This research explores how AI and ML models may increase the accuracy and reliability of recurrence prediction in cancer. Therefore, AI and ML create new opportunities not only for personalized medicine but also for proactive management of patients through analyzing large volumes of data on genetics, clinical manifestations, and treatment. The paper describes the various AI and ML techniques for pattern identification and outcome prediction in cancer patients using supervised and unsupervised learning. Clinical implications provide an opportunity to review how early interventions could happen and the design of treatment planning.

Treating cancer is one of the most challenging task in medical sciences. Only limited types of cancer treatments are available as their study is still ongoing. The earlier therapies like radiotherapy with x-rays, chemotherapy are associated with lot of side-effects. One of the most desirable cancer treatment is using particle beam therapies. These therapies are quite less risky than other types of cancer and tumor treatments. In this paper we present the proton and carbon-12 ion beam simulation that can help in tumor and cancer treatment. We simulated the proton and carbon-12 ion beam in water and soft tissue using geant4 toolkit. The protons are observed to have much better energy deposition in the water and soft tissue than carbon-12 ion and gamma photon beams.

Cervical cancer presents a significant global health challenge, necessitating advanced diagnostic and prognostic approaches for effective treatment. This paper investigates the potential of employing multi-modal medical imaging at various treatment stages to enhance cervical cancer treatment outcomes prediction. We show that among Gray Level Co-occurrence Matrix (GLCM) features, contrast emerges as the most effective texture feature regarding prediction accuracy. Integration of multi-modal imaging and texture analysis offers a promising avenue for personalized and targeted interventions, as well as more effective management of cervical cancer. Moreover, there is potential to reduce the number of time measurements and modalities in future cervical cancer treatment. This research contributes to advancing the field of precision diagnostics by leveraging the information embedded in noninvasive medical images, contributing to improving prognostication and optimizing therapeutic strategies for individuals diagnosed with cervical cancer.

The aim is to create a method for accurately estimating the duration of post-cancer treatment, particularly focused on chemotherapy, to optimize patient care and recovery. This initiative seeks to improve the effectiveness of cancer treatment, emphasizing the significance of each patient's journey and well-being. Our focus is to provide patients with valuable insight into their treatment timeline because we deeply believe that every life matters. We combined medical expertise with smart technology to create a model that accurately predicted each patient's treatment timeline. By using machine learning, we personalized predictions based on individual patient details which were collected from a regional government hospital named Sylhet M.A.G. Osmani Medical College & Hospital, Sylhet, Bangladesh, improving cancer care effectively. We tackled the challenge by employing around 13 machine learning algorithms and analyzing 15 distinct features, including LR, SVM, DT, RF, etc. we obtained a refined precision in predicting cancer patient's treatment durations. Furthermore, we utilized ensemble techniques to reinforce the accuracy of our methods. Notably, our study revealed that our majo

Cancer treatment is at the core a sequential decision-making problem with partial observability, latent patient heterogeneity, and explicit constraints on the budget for medical measurements. Unlike standard Reinforcement Learning (RL) approaches that control state trajectories, cancer treatments permanently modify patients' transition dynamics, changing how states evolve over time. We model cancer treatment as a belief-space planning problem using active inference, deriving an expected free-energy objective that unifies goal-directed control and information acquisition under measurement budgets without. We implement this framework using real clinical cancer data from the AACR Project GENIE Biopharma Collaborative dataset. Results on clinical data demonstrate a simultaneous patient categorization and high treatment efficacy, under real measurement and treatment constraints.

Due to silence in early stages, lung cancer has been one of the most leading causes of mortality in cancer patients world-wide. Moreover, major symptoms of lung cancer are hard to differentiate with other respiratory disease symptoms such as COPD, further leading patients to overlook cancer progression in early stages. Thus, to enhance survival rates in lung cancer, early detection from consistent proactive respiratory system monitoring becomes crucial. One of the most prevalent and effective methods for lung cancer monitoring would be low-dose computed tomography(LDCT) chest scans, which led to remarkable enhancements in lung cancer detection or tumor classification tasks under rapid advancements and applications of computer vision based AI models such as EfficientNet or ResNet in image processing. However, though advanced CNN models under transfer learning or ViT based models led to high performing lung cancer detections, due to its intrinsic limitations in terms of correlation dependence and low interpretability due to complexity, expansions of deep learning models to lung cancer treatment analysis or causal intervention analysis simulations are still limited. Therefore, this re

In recent years, cancer genome sequencing and other high-throughput studies of cancer genomes have generated many notable discoveries. In this review, Novel genomic alteration mechanisms, such as chromothripsis (chromosomal crisis) and kataegis (mutation storms), and their implications for cancer are discussed. Genomic alterations spur cancer genome evolution. Thus, the relationship between cancer clonal evolution and cancer stems cells is commented. The key question in cancer biology concerns how these genomic alterations support cancer development and metastasis in the context of biological functioning. Thus far, efforts such as pathway analysis have improved the understanding of the functional contributions of genetic mutations and DNA copy number variations to cancer development, progression and metastasis. However, the known pathways correspond to a small fraction, plausibly 5-10%, of somatic mutations and genes with an altered copy number. To develop a comprehensive understanding of the function of these genomic alterations in cancer, an integrative network framework is proposed and discussed. Finally, the challenges and the directions of studying cancer omic data using an in

Treatments for breast cancer have continued to evolve and improve in recent years, resulting in a substantial increase in survival rates, with approximately 80\% of patients having a 10-year survival period. Given the serious impact that breast cancer treatments can have on a patient's body image, consequently affecting her self-confidence and sexual and intimate relationships, it is paramount to ensure that women receive the treatment that optimizes both survival and aesthetic outcomes. Currently, there is no gold standard for evaluating the aesthetic outcome of breast cancer treatment. In addition, there is no standard way to show patients the potential outcome of surgery. The presentation of similar cases from the past would be extremely important to manage women's expectations of the possible outcome. In this work, we propose a deep neural network to perform the aesthetic evaluation. As a proof-of-concept, we focus on a binary aesthetic evaluation. Besides its use for classification, this deep neural network can also be used to find the most similar past cases by searching for nearest neighbours in the highly semantic space before classification. We performed the experiments on

Cancer is a fatal disease caused by a combination of genetic diseases and a variety of biochemical abnormalities. Lung and colon cancer have emerged as two of the leading causes of death and disability in humans. The histopathological detection of such malignancies is usually the most important component in determining the best course of action. Early detection of the ailment on either front considerably decreases the likelihood of mortality. Machine learning and deep learning techniques can be utilized to speed up such cancer detection, allowing researchers to study a large number of patients in a much shorter amount of time and at a lower cost. In this research work, we introduced a hybrid ensemble feature extraction model to efficiently identify lung and colon cancer. It integrates deep feature extraction and ensemble learning with high-performance filtering for cancer image datasets. The model is evaluated on histopathological (LC25000) lung and colon datasets. According to the study findings, our hybrid model can detect lung, colon, and (lung and colon) cancer with accuracy rates of 99.05%, 100%, and 99.30%, respectively. The study's findings show that our proposed strategy ou

Cancer is one of the most widespread diseases around the world with millions of new patients each year. Bladder cancer is one of the most prevalent types of cancer affecting all individuals alike with no obvious prototypical patient. The current standard treatment for BC follows a routine weekly Bacillus Calmette-Guerin (BCG) immunotherapy-based therapy protocol which is applied to all patients alike. The clinical outcomes associated with BCG treatment vary significantly among patients due to the biological and clinical complexity of the interaction between the immune system, treatments, and cancer cells. In this study, we take advantage of the patient's socio-demographics to offer a personalized mathematical model that describes the clinical dynamics associated with BCG-based treatment. To this end, we adopt a well-established BCG treatment model and integrate a machine learning component to temporally adjust and reconfigure key parameters within the model thus promoting its personalization. Using real clinical data, we show that our personalized model favorably compares with the original one in predicting the number of cancer cells at the end of the treatment, with 14.8% improvem

We present a general computational theory of cancer and its developmental dynamics. The theory is based on a theory of the architecture and function of developmental control networks which guide the formation of multicellular organisms. Cancer networks are special cases of developmental control networks. Cancer results from transformations of normal developmental networks. Our theory generates a natural classification of all possible cancers based on their network architecture. Each cancer network has a unique topology and semantics and developmental dynamics that result in distinct clinical tumor phenotypes. We apply this new theory with a series of proof of concept cases for all the basic cancer types. These cases have been computationally modeled, their behavior simulated and mathematically described using a multicellular systems biology approach. There are fascinating correspondences between the dynamic developmental phenotype of computationally modeled {\em in silico} cancers and natural {\em in vivo} cancers. The theory lays the foundation for a new research paradigm for understanding and investigating cancer. The theory of cancer networks implies that new diagnostic methods

Nanorobots are a promising development in targeted drug delivery and the treatment of neurological disorders, with potential for crossing the blood-brain barrier (BBB). These small devices leverage advancements in nanotechnology and bioengineering for precise navigation and targeted payload delivery, particularly for conditions like brain tumors, Alzheimer's disease, and Parkinson's disease. Recent progress in artificial intelligence (AI) and machine learning (ML) has improved the navigation and effectiveness of nanorobots, allowing them to detect and interact with cancer cells through biomarker analysis. This study presents a new reinforcement learning (RL) framework for optimizing nanorobot navigation in complex biological environments, focusing on cancer cell detection by analyzing the concentration gradients of surrounding biomarkers. We utilize a computer simulation model to explore the behavior of nanorobots in a three-dimensional space with cancer cells and biological barriers. The proposed method uses Q-learning to refine movement strategies based on real-time biomarker concentration data, enabling nanorobots to autonomously navigate to cancerous tissues for targeted drug d

Motile nanosized particles, or "nanobots", promise more effective and less toxic targeted drug delivery because of their unique scale and precision. We consider the case in which the cancer is "diffuse", dispersed such that there are multiple distinct cancer sites. We investigate the problem of a swarm of nanobots locating these sites and treating them by dropping drug payloads at the sites. To improve the success of the treatment, the drug payloads must be allocated between sites according to their "demands"; this requires extra nanobot coordination. We present a mathematical model of the behavior of the nanobot agents and of their colloidal environment. This includes a movement model for agents based upon experimental findings from actual nanoparticles in which bots noisily ascend and descend chemical gradients. We present three algorithms: The first algorithm, called KM, is the most representative of reality, with agents simply following naturally existing chemical signals that surround each cancer site. The second algorithm, KMA, includes an additional chemical payload which amplifies the existing natural signals. The third algorithm, KMAR, includes another additional chemical

The treatment of cancer is one of the most discussed issues in the realm of contemporary public health research. One of the primary concerns of both the general public and the government is the development of the most effective cancer treatment at the most affordable price. This is due to the fact that the number of persons diagnosed with cancer increases on an annual basis. Within the scope of this project, we propose the development of a system for the recommendation of treatment centers. This system would initially select patients who posed a higher risk value, and then it would recommend the most appropriate cancer treatment center for those patients based on their income and the location where they lived using a stable matching algorithm.

With the advances in artificial intelligence (AI), data-driven algorithms are becoming increasingly popular in the medical domain. However, due to the nonlinear and complex behavior of many of these algorithms, decision-making by such algorithms is not trustworthy for clinicians and is considered a black-box process. Hence, the scientific community has introduced explainable artificial intelligence (XAI) to remedy the problem. This systematic scoping review investigates the application of XAI in breast cancer detection and risk prediction. We conducted a comprehensive search on Scopus, IEEE Explore, PubMed, and Google Scholar (first 50 citations) using a systematic search strategy. The search spanned from January 2017 to July 2023, focusing on peer-reviewed studies implementing XAI methods in breast cancer datasets. Thirty studies met our inclusion criteria and were included in the analysis. The results revealed that SHapley Additive exPlanations (SHAP) is the top model-agnostic XAI technique in breast cancer research in terms of usage, explaining the model prediction results, diagnosis and classification of biomarkers, and prognosis and survival analysis. Additionally, the SHAP mo

Path integral control is an effective method in cancer drug treatment, providing a structured approach to handle the complexities and unpredictability of tumor behavior. Utilizing mathematical principles from physics, this technique optimizes drug delivery in environments influenced by randomness. It takes into account the intricate interactions between cancer cells, healthy tissues, and the immune system, as well as factors such as patient-specific characteristics and tumor diversity. Path integral control offers tailored solutions to these issues, enabling the design of drug dosing regimens that enhance therapeutic effectiveness while minimizing side effects. Its flexibility makes it a valuable tool in creating personalized, precision-driven therapies, ultimately improving patient outcomes in cancer treatment. In this paper we give a review about the current status of path integral control in cancer research.

Cancer research reflects an implicit conflict. On the one hand, there is an overwhelming desire to control the disease. We all wish that. On the other hand, we would like to understand why cancer follows so many clearly defined yet puzzling patterns. Why is there such regularity in the rates of progression? Why do different tissues vary so much? There should, of course, be no conflict between control and understanding. But the history of cancer research seems to say that those different goals remain oddly estranged. Peto's 1977 article locates the seeds of this conflict most clearly. He describes what is still the most powerful theoretical perspective for analyzing the causes of cancer. He presents many key unsolved puzzles within that context. He also says why most cancer researchers are not interested in these fundamental issues. The subsequent decades of research grew around this rift, blindly, in the way that research disciplines often grow. Let us revisit Peto, almost 40 years ago. We can learn much about the current nature of cancer research.

The long-term efficacy of targeted therapeutics for cancer treatment can be significantly limited by the type of therapy and development of drug resistance, inter alia. Experimental studies indicate that the factors enhancing acquisition of drug resistance in cancer cells include cell heterogeneity, drug target alteration, drug inactivation, DNA damage repair, drug efflux, cell death inhibition, as well as microenvironmental adaptations to targeted therapy, among others. Combination cancer therapies (CCTs) are employed to overcome these molecular and pathophysiological bottlenecks and improve the overall survival of cancer patients. CCTs often utilize multiple combinatorial modes of action and thus potentially constitute a promising approach to overcome drug resistance. Considering the colossal cost, human effort, time and ethical issues involved in clinical drug trials and basic medical research, mathematical modeling and analysis can potentially contribute immensely to the discovery of better cancer treatment regimens. In this article, we review mathematical models on CCTs developed thus far for cancer management. Open questions are highlighted and plausible combinations are disc

We present a new mathematical model of colorectal cancer growth and its response to monoclonal-antibody (mAb) therapy. Although promising, most mAb drugs are still in trial phases, and the possible variations in the dosing schedules of those currently approved for use have not yet been thoroughly explored. To investigate the effectiveness of current mAb treatment schedules, and to test hypothetical treatment strategies, we have created a system of nonlinear ordinary differential equations (ODE) to model colorectal cancer growth and treatment. The model includes tumor cells, elements of the host's immune response, and treatments. Model treatments include the chemotherapy agent irinotecan and one of two monoclonal antibodies - cetuximab, which is FDA-approved for colorectal cancer, and panitumumab, which is still being evaluated in clinical trials. The model incorporates patient-specific parameters to account for individual variations in immune system strength and in medication efficacy against the tumor. We have simulated outcomes for groups of virtual patients on treatment protocols for which clinical trial data are available, using a range of biologically reasonable patient-specif